Skip to content

EJHP Highlights: Telaprevir and Boceprevir for treatment of Hepatitis C

Ahead of the WHO’s World Hepatitis Day, EAHP’s EU Monitor highlights a recent EJHP article by Mark Nolan on the use of antiviral protease inhibitors Telaprevir and Boceprevir for the treatment of Hepatitis C.
The article discus

ses some of the special points about both medicines, including patient counselling around such issues as adverse reactions, drug interactions and medication storage.

Full article available here

×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.